Standalone Audited Financial Results for the quarter and year ended March 31, 2026.
LOTUSEYE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.7 pts less than Nifty Microcap 250 and 0.8 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Lotus Eye Hospital reported strong financial performance for FY2026 with total income of Rs. 5,489.03 lakhs, up 7.9% from Rs. 5,086.38 lakhs in FY2025. Revenue from operations grew 8.4% to Rs. 5,371.41 lakhs. Net profit surged significantly to Rs. 73.93 lakhs from Rs. 25.23 lakhs in the previous year, driven by improved operational efficiency. For Q4 FY2026 alone, revenue was Rs. 1,360.92 lakhs with net profit of Rs. 27.99 lakhs. The statutory auditor issued an unmodified (clean) opinion confirming true and fair view of financial statements. The company spent heavily on capital expenditure (Rs. 1,294.91 lakhs on PPE) during the year, funded partly through increased long-term borrowings.
Positive signal for shareholders as net profit nearly tripled year-on-year, indicating improved profitability and operational efficiency. The clean audit opinion removes any concerns about financial reporting quality.